Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Biotherapeutics Clinical Site 207
Surrey, British Columbia, Canada
- Arcutis Biotherapeutics Clinical Site 226
Surrey, British Columbia, Canada
- Arcutis Biotherapeutics Clinical Site 232
Winnepeg, Manitoba, Canada
- Arcutis Biotherapeutics Clinical Site 234
Fredericton, New Brunswick, Canada
- Arcutis Biotherapeutics Clinical Site 205
Ajax, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 218
Barrie, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 235
Toronto, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 204
Windsor, Ontario, Canada
- Arcutis Biotherapeutics Clinical Site 203
Scottsdale, Arizona, United States
- Arcutis Biotherapeutics Clinical Site 239
Beverly Hills, California, United States
- Arcutis Biotherapeutics Clinical Site 225
Encino, California, United States
- Arcutis Biotherapeutics Clinical Site 220
San Diego, California, United States
- Arcutis Biotherapeutics Clinical Site 208
Santa Monica, California, United States
- Arcutis Biotherapeutics Clinical Site 215
Santa Monica, California, United States
- Arcutis Biotherapeutics Clinical Site 223
Boynton Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 237
DeLand, Florida, United States
- Arcutis Biotherapeutics Clinical Site 228
Largo, Florida, United States
- Arcutis Biotherapeutics Clinical Site 201
North Miami Beach, Florida, United States
- Arcutis Biotherapeutics Clinical Site 209
Sweetwater, Florida, United States
- Arcutis Biotherapeutics Clinical Site 214
Indianapolis, Indiana, United States
- Arcutis Biotherapeutics Clinical Site 217
Louisville, Kentucky, United States
- Arcutis Biotherapeutics Clinical Site 211
Lake Charles, Louisiana, United States
- Arcutis Biotherapeutics Clinical Site 213
Metairie, Louisiana, United States
- Arcutis Biotherapeutics Clinical Site 224
New Orleans, Louisiana, United States
- Arcutis Biotherapeutics Clinical Site 212
Detroit, Michigan, United States
- Arcutis Biotherapeutics Clinical Site 216
Fridley, Minnesota, United States
- Arcutis Biotherapeutics Clinical Site 227
Saint Joseph, Missouri, United States
- Arcutis Biotherapeutics Clinical Site 219
Las Vegas, Nevada, United States
- Arcutis Biotherapeutics Clinical Site 231
Las Vegas, Nevada, United States
- Arcutis Biotherapeutics Clinical Site 240
Reno, Nevada, United States
- Arcutis Biotherapeutics Clinical Site 236
Portsmouth, New Hampshire, United States
- Arcutis Biotherapeutics Clinical Site 222
Oklahoma City, Oklahoma, United States
- Arcutis Biotherapeutics Clinical Site 229
Broomall, Pennsylvania, United States
- Arcutis Biotherapeutics Clinical Site 233
Knoxville, Tennessee, United States
- Arcutis Biotherapeutics Clinical Site 221
Murfreesboro, Tennessee, United States
- Arcutis Biotherapeutics Clinical Site 206
Arlington, Texas, United States
- Arcutis Biotherapeutics Clinical Site 238
Houston, Texas, United States
- Arcutis Biotherapeutics Clinical Site 210
West Jordan, Utah, United States
- Arcutis Biotherapeutics Clinical Site 230
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Dec 2019
- Primary completion
- 23 Nov 2020
- Completion
- 23 Nov 2020
- Last update posted
- 7 Dec 2022
- Registered enrollment
- 442
- Registry id
- NCT04211389
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.